Tissue Renin-Angiotensin Systems in the Pathophysiology of Heart Failure

  • A. T. Hirsch
  • V. J. Dzau
Conference paper

Abstract

It is well documented that a reduction in cardiac output elicits compensatory homeostatic responses that are mediated by neurohormonal mechanisms. Activation of the sympathetic nervous system results in systemic vasoconstriction, decreases in renal blood flow and glomerular filtration rate, and an increase in tubular reabsorption of sodium [1]. Activation of the renin-angiotensin system (RAS) contributes further to the increases in vascular tone and sodium avidity. While vasopressin secretion may also be increased during marked reductions in cardiac output, it is unlikely that this hormone contributes significantly to the maintainance of systemic vasoconstriction, as compared to its effects on sodium and water homeostasis [2–4]. The temporal activation of circulating neurohormonal mechanisms are well-illustrated by the study of Watkins et al., in the experimental canine model of cardiac decompensation [5]. In this model, reductions in cardiac output and filling pressure result in the elevations of plasma renin activity and angiotensin II (All) aldosterone, norepinephrine, and vasopressin levels that are associated with vasoconstriction and sodium retention. However, these circulating neurohormonal mechanisms return toward normal during the compensated stage of heart failure as plasma volume and cardiac stroke volume increase. Thus, in experimental heart failure, circulating neurohormonal mechanisms exhibit a time-dependent response, with acute activation and subsequent normalization during the chronic, compensated phase (Fig. 1).

Keywords

Angiotensin Norepinephrine Catecholamine Cardiol Propranolol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    DiBona GF (1977) Neurogenic regulation of renal tubular sodium reabsorption. Am J Physiol 233: 173–181Google Scholar
  2. 2.
    Creager MA (1986) The role of vasopressin in congestive heart failure. Heart Failure 2: 14–20Google Scholar
  3. 3.
    Hirsch AT, Cant JR, Dzau VJ, Barger AC (1988) Sequential cardiorenal responses to rapid ventricular pacing in the conscious dog. FASEB J 2: A829Google Scholar
  4. 4.
    Paganelli W, Creager MA, Dzau VJ (1986) Cardiac regulation of kidney function. In: Cheung TO (ed) International textbook of cardiology. Gower, London, pp 918–922Google Scholar
  5. 5.
    Watkins IJ, Burton JA, Haber E, Cant JR, Smith FM, Barger AC (1976) The renin-aldosterone system in congestive heart failure in conscious dogs. J Clin Invest 57: 1606–1617PubMedCrossRefGoogle Scholar
  6. 6.
    Dzau VJ, Colucci WS, Hollenberg NK, Williams GH (1981) Relation of the renin-angiotensin- aldosterone system to clinical state in congestive heart failure. Circulation 63: 645–651PubMedCrossRefGoogle Scholar
  7. 7.
    Hodsman GP, Kohzuki M, Howes LG, Sumithran E, Tsunoda K, Johnston CI (1988) Neurohormonal responses to chronic myocardial infarction in rats. Circulation 78: 376–381PubMedCrossRefGoogle Scholar
  8. 8.
    Hirsch AT, Talsness C, Lage A, Dzau VJ (1989) The effect of experimental myocardial infarction and chronic captopril treatment on plasma and tissue angiotensin converting-en- zyme activity. Clin Res 37: 266A (abstract)Google Scholar
  9. 9.
    Deboben A, Inagami T, Ganten G (1983) Tissue renin. In: Genest J, Kuchel O, Hamet P (eds) Hypertension, 2nd edn. McGraw-Hill, New York, pp 194–209Google Scholar
  10. 10.
    Philips MI, Stenstrom B (1985) Angiotensin II in rat brain comigrates with authentic angiotensin II in high pressure liquid chromatography. Circ Res 56: 212–219Google Scholar
  11. 11.
    Dzau VJ, Ellison KE, Brody T, Ingelfinger J, Pratt RE (1987) A comparative study of the distributions of renin and angiotensinogen messenger ribonucleic acids in rat and mouse tissues. Endocrinology 120: 2334–2338PubMedCrossRefGoogle Scholar
  12. 12.
    Field LS, McGowen RA, Dickenson DP, Gross KW (1984) Tissue and gene specificity of mouse renin expression. Hypertension 6: 597–603PubMedGoogle Scholar
  13. 13.
    Lynch KR, Simnad VT, Ben-Ari ET, Maniatis R, Zinn K, Garrison JC (1986) Localization of preangiotensinogen messenger RNA sequences in the rat brain. Hypertension 8: 540–543PubMedGoogle Scholar
  14. 14.
    Loudon M, Bing RF, Thurston H, Swales JD (1983) Arterial wall uptake of renal renin and blood pressure control. Hypertension 5: 629–634PubMedGoogle Scholar
  15. 15.
    Oliver JA, Sciacca RR (1984) Local generation of angiotensin II as a mechanism of regulation of peripheral vascular tone in the rat. J Clin Invest 74: 1247–1251PubMedCrossRefGoogle Scholar
  16. 16.
    Dzau VJ, Gibbons GH (1987) Autocrine-paracrine mechanisms of vascular myocytes in hypertension. Am J Cardiol 60:991 –1031Google Scholar
  17. 17.
    Rosenthal JH, Pfeiffer B, Mecheilor ML, Pschorr J, Jacob ICM, Dahlheim H (1984) Investigations of components of the renin-angiotensin system in rat vascular tissue. Hypertension 6: 383–390PubMedGoogle Scholar
  18. 18.
    Molteni A, Dzau VJ, Fallon JT, Haber E (1984) Monoclonal antibodies as probes of renin gene expression. Circulation 70 [Suppl II]: 11–196Google Scholar
  19. 19.
    Aguirela G, Schirer A, Baukai A, Gatt KJ (1981) Circulating angiotensin II and adrenal receptors after nephrectomy. Nature 289: 507–509CrossRefGoogle Scholar
  20. 20.
    Campbell DJ (1985) The site of angiotensin production. J Hypertens 3: 730–737CrossRefGoogle Scholar
  21. 21.
    Malik KU, Masjletti A (1976) Facilitation of adrenergic transmission by locally generated angiotensin II in rat mesenteric arteries. Circ Res 60 (3): 422–428Google Scholar
  22. 22.
    Zimmerman BG (1981) Adrenergic facilitation by angiotensin. Does it serve a physiological function? Clin Sci 60: 343–348PubMedGoogle Scholar
  23. 23.
    Kawasaki H, Cline WH Jr, Su C (1984) Involvement of the vascular renin-angiotensin system in beta adrenergic receptor-mediated facilitation of vascular neurotransmission in spontaneously hypertensive rats. J Pharmacol Exp Ther 231: 23–32PubMedGoogle Scholar
  24. 24.
    Nakamura M, Jackson EK, Inagami T (1986) Beta adrenoreceptor mediated release of angiotensin II from mesenteric arteries. Am J Physiol 250: H144–H148Google Scholar
  25. 25.
    Longnecker DI, Durcus MI, Donovan KR, Miller ED, Peach MJ (1984) Saralasin dilates arterioles in SHR but not WKY rats. Hypertension I [Suppl 1]: 106–110Google Scholar
  26. 26.
    Riegger AJG, Lever AF, Miller JA, Morton JJ, Slack B (1977) Correction of renal hypertension in the rat by prolonged infusion of saralasin. Lancet 2: 1317–1319PubMedCrossRefGoogle Scholar
  27. 27.
    Okamura T, Miyazcki M, Inagemi T, Toda N (1986) Vascular renin-angiotensin system in two-kidney, one clip hypertensive rates. Hypertension 8: 560–565PubMedGoogle Scholar
  28. 28.
    Unger T, Ganten D, Lang RE, Scholkens VA (1985) Is tissue converting inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with two different compounds. Hoe 398 and MD 421 in spontaneously hypertensive rats. J Cardiovasc Pharmacol 7: 36–41PubMedCrossRefGoogle Scholar
  29. 29.
    Simon ACH, Levenson JA, Bouther JI, Safar ME (1984) Comparison of oral MK 421 and propranolol in mild to moderate hypertension and their effects on arterial and venous vessels of the forearm. Am J Cardiol 53: 781–783PubMedCrossRefGoogle Scholar
  30. 30.
    Dzau VJ, Safar MI (1988) Large conduit arteries in hypertension; role of the vascular renin angiotensin system. Circulation 77: 947–954PubMedCrossRefGoogle Scholar
  31. 31.
    Dzau VJ, Re RN (1987) Evidence for the existence of renin in the heart. Circulation 73 [Suppl I]: 134–136Google Scholar
  32. 32.
    Piccini N, Knopf JL, Gross KW (1982) A DNA polmorphism, consistent with gene duplications, correlates with renin levels in the mouse submaxillary gland. Cell 30: 205PubMedCrossRefGoogle Scholar
  33. 33.
    Ohkubo H, Nakayama K, Tanaka T, Nakanishi S (1986) Tissue distribution of rat an- giotensinogen mRNA and structural analysis of its heterogeneity. J Biol Chem 261: 319–323PubMedGoogle Scholar
  34. 34.
    Cohen L, Kurz KD (1982) Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK-421. J Pharmacol Exp Ther 220: 63–69PubMedGoogle Scholar
  35. 35.
    Unger T, Demmert G, Fleet T (1984) Role of tissue converting enzyme inhibition for the antihypertensive action of Hoe 498 and MK 421 in spontaneously hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol 325 [Suppl]: 216Google Scholar
  36. 36.
    Linz W, Scholkens BA, Han YI (1986) Beneficial effects of the converting enzyme inhibition, ramipril in ischemic rat hearts. J Cardiovasc Pharmacol 8 [Suppl 10]: 591–599Google Scholar
  37. 37.
    Rogers TB, Gaa S, Allen IS (1986) Identification and characterization of functional angiotensin II receptors on cultured heart myocytes. J Pharmacol Exp Ther 236: 438–444PubMedGoogle Scholar
  38. 38.
    Urata H, Healy B, Stewart RW, Bumpus FM, Husain A (1989) Angiotensin II receptors in normal and failing human hearts. J Clin Endocrinol Metab 69: 54–66PubMedCrossRefGoogle Scholar
  39. 39.
    Dzau VJ, Ellison KE, Ouellette AJ (1985) Expression and regulation of renin in the mouse heart. Clin Res 33: 181A (abstract)Google Scholar
  40. 40.
    Assad MM, Antonaccio MJ (1982) Vascular wall renin in spontaneously hypertensive rats: potential relevance to hypertension maintenance and antihypertensive effect of captopril. Hypertension 4: 487–493Google Scholar
  41. 41.
    Lorell BH, Schunkert H, Grice WN, Tang SS, Abstein CS, Dzau VJ (1989) Alteration in cardiac angiotensin converting enzyme activity in pressure overload hypertrophy. Circulation 80 [Suppl II]: 11–297 (abstract)Google Scholar
  42. 42.
    Drexler H, Hanze J, Finch M, Lu W, Just H, Lang RE (1989) Atrial natriuretic peptide in a rat model of cardiac failure. Circulation 79: 620–633PubMedCrossRefGoogle Scholar
  43. 43.
    Van Gilst WH, deGraeff PA, Wessling H, deLangen CDJ (1987) Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: a comparison of Captopril, enalapril and HOE 498. J Cardiovasc Pharmacol 9: 254–255PubMedCrossRefGoogle Scholar
  44. 44.
    Baker KM, Khosla MC (1986) Cardiac and vascular actions of decapeptide angiotensin analogs. J Pharmacol Exp Ther 239: 790–796PubMedGoogle Scholar
  45. 45.
    Koch-Weser J (1965) Nature of the inotropic action of angiotensin on ventricular myocardium. Circ Res 16: 230–237PubMedGoogle Scholar
  46. 46.
    Koch-Weser J (1964) Myocardial actions of angiotensin II. Circ Res 14: 337–344PubMedGoogle Scholar
  47. 47.
    Ziogas J, Story DF, Rand MJ (1985) Effects of locally generated All on noradrenergic transmission in guinea pig isolated atria. Eur J Pharmacol 106: 11–18CrossRefGoogle Scholar
  48. 48.
    Ziang J, Linz W, Becker H, Ganten D, Lang RE, Schoelkens B, Unger T (1984) Effects of converting enzyme inhibitors: ramipril and enalapril on peptide action and sympathetic neurotransmission in the isolated rat heart. Eur J Pharmacol 113: 215–223Google Scholar
  49. 49.
    Naftilan AJ, Pratt RJ, Eldridge CS, Lin HL, Dzau VJ (1989) Angiotensin II induces c-fos expression in smooth muscle via transcriptional control. Hypertension 13: 706–711PubMedGoogle Scholar
  50. 50.
    Tarazi RC, Fouad FM (1984) Reversal of cardiac hypertrophy. Hypertension 6 [Suppl III]: III-140–III-145Google Scholar
  51. 51.
    Ingelfinger JR, Pratt RE, Ellison K, Dzau VJ (1986) Sodium regulation of angiotensinogen mRNA expression in rat kidney cortex and medulla. J Clin Invest 78: 1311–1315PubMedCrossRefGoogle Scholar
  52. 52.
    Taugner R, Hackenthal E, Helmchen U, Ganten D, Kugler P, Marin-Grez M, Nobiling R, Unger T, Lockwald I, Keilbach R (1982) The intrarenal renin-angiotensin system. An immunocytochemical study on the localization of renin, angiotensinogen, converting enzyme, and the angiotensins in the kidney of mouse and rat. Klin Wochenschr 60: 1218–1222PubMedCrossRefGoogle Scholar
  53. 53.
    Dzau VJ, Kreisberg JI (1986) Cultured glomerular mesangial cells contain renin: influence of calcium and isoproterenol. J Cardiovasc Pharmacol 8 [Suppl 10]: S6–S10PubMedCrossRefGoogle Scholar
  54. 54.
    Liu FY, Cogan MG (1987) Angiotensin II: a potent regulator of acidification in the rat early proximal convoluted tubule. J Clin Invest 80: 273–275CrossRefGoogle Scholar
  55. 55.
    Schunkert H, Hirsch AT, Mankadi S, Talsness C, Dzau VJ (1989) Renal angiotensinogen gene expression in experimental heart failure: effect of angiotensin converting-enzyme inhibition. Clin Res 37: 584AGoogle Scholar
  56. 56.
    Hostetter TH, Pfeffer JM, Pfeffer MA, Dworkin LD, Braunwald E, Brenner BM (1983) Cardiorenal hemodynamics and sodium excretion in rats with myocardial infarction. Am J Physiol 245: H98–H103PubMedGoogle Scholar
  57. 57.
    Ichikawa I, Pfeffer JM, Pfeffer MA, Hostetter TH, Brenner BM (1984) Role of angiotensin II in the altered renal function of congestive heart failure. Circ Res 55: 669–675PubMedGoogle Scholar
  58. 58.
    The CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe heart failure. N Engl J Med 316: 1429–1431CrossRefGoogle Scholar
  59. 59.
    Pfeffer JM, Pfeffer MA, Braunwald E (1985) Influence of chronic Captopril therapy on the infarcted left ventricle of the rat. Circ Res 57: 84–95PubMedGoogle Scholar
  60. 60.
    Pfeffer MA, Lamas GA, Vaughn DE, Parisi AF, Braunwald E (1988) Effect of Captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 319: 80–86PubMedCrossRefGoogle Scholar
  61. 61.
    Sharpe N, Murphy J, Smith H, Hannan S (1988) Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 1 (8580): 255–259PubMedCrossRefGoogle Scholar
  62. 62.
    Cushman DW, Wang FL, Fung WC, Harvey CM, DeForrest JM (1989) Differentiation of angiotensin-converting enzyme ( ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am J Hypertens 2: 294–306PubMedGoogle Scholar
  63. 63.
    Massie BM, Kramer BL, Topic N (1984) Lack of relationship between the short-term hemodynamic effects of Captopril and subsequent clinical responses. Circulation 69: 1135–1141PubMedCrossRefGoogle Scholar
  64. 64.
    Creager MA, Faxon DP, Halperin SL et al. (1982) Determinants of clinical response and survival in patients with congestive heart failure treated with Captopril. Am Heart J 104: 1147–1153PubMedCrossRefGoogle Scholar
  65. 65.
    Packer M, Lee WH, Yushak M, Medina N (1981) Comparison of Captopril and enalapril in patients with severe chronic heart failure. N Engl J Med 315: 847–853CrossRefGoogle Scholar
  66. 66.
    Giles TG, Katz R, Sullivan JM, Wolfson P et al. (1989) Short- and long-acting angiotensin converting enzyme inhibitors: a randomized trial of lisinopril versus Captopril in the treatment of congestive heart failure. J Am Coll Cardiol 13: 1240–1247PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • A. T. Hirsch
  • V. J. Dzau

There are no affiliations available

Personalised recommendations